Medicina,
Год журнала:
2020,
Номер
56(5), С. 237 - 237
Опубликована: Май 15, 2020
Cannabis
has
been
used
for
centuries
therapeutic
purposes.
In
the
last
century,
plant
was
demonized
due
to
its
high
abuse
liability
and
supposedly
insufficient
health
benefits.
However,
recent
decriminalization
policies
new
scientific
evidence
have
increased
interest
in
cannabis
potential
of
paved
way
release
marketing
authorizations
cannabis-based
products.
Although
several
synthetic
standardized
products
are
currently
available
on
market,
patients’
preferences
lean
towards
herbal
preparations,
because
they
easy
handle
self-administer.
A
literature
search
conducted
multidisciplinary
research
databases
international
agencies
or
institutional
websites.
Despite
growing
popularity
medical
cannabis,
little
data
is
chemical
composition
preparation
methods
extracts.
The
authors
hereby
report
most
common
presenting
their
indications,
routes
administration
recommended
dosages.
practical
helpful
guide
prescribing
doctors
provided,
including
suggested
posology,
titration
strategies
cannabinoid
amounts
preparations
obtained
from
different
sources
cannabis.
Cancers,
Год журнала:
2020,
Номер
12(7), С. 1985 - 1985
Опубликована: Июль 21, 2020
In
recent
years,
and
even
more
since
its
legalization
in
several
jurisdictions,
cannabis
the
endocannabinoid
system
have
received
an
increasing
amount
of
interest
related
to
their
potential
exploitation
clinical
settings.
Cannabinoids
been
suggested
shown
be
effective
treatment
various
conditions.
cancer,
is
altered
numerous
types
tumours
can
relate
cancer
prognosis
disease
outcome.
Additionally,
cannabinoids
display
anticancer
effects
models
by
suppressing
proliferation,
migration
and/or
invasion
cells,
as
well
tumour
angiogenesis.
However,
therapeutic
use
currently
limited
symptoms
pain
associated
with
chemotherapy,
while
cytotoxic
drugs
chemotherapy
still
requires
validation
patients.
Along
cannabinoids,
contains
other
compounds
that
also
exert
anti-tumorigenic
actions.
The
anti-cancer
terpenes
flavonoids,
present
cannabis,
are
explored
this
literature
review.
Behavioural Neurology,
Год журнала:
2019,
Номер
2019, С. 1 - 13
Опубликована: Ноя. 21, 2019
Neuropathic
pain
is
a
chronic
secondary
condition,
which
consequence
of
peripheral
or
central
nervous
(somatosensory)
system
lesions
diseases.
It
devastating
affects
around
7%
the
general
population.
Numerous
etiological
factors
contribute
to
development
neuropathic
pain.
can
originate
from
part
such
as
in
case
trigeminal
postherpetic
neuralgia,
nerve
injury,
painful
polyneuropathies,
radiculopathies.
Central
develop
result
spinal
cord
brain
stroke,
multiple
sclerosis.
As
first-line
pharmacological
treatment
options,
tricyclic
antidepressants,
serotonin-norepinephrine
reuptake
inhibitors,
and
gabapentinoids
are
recommended.
In
carbamazepine
oxcarbazepine
first-choice
drugs.
drug-refractory
cases,
interventional,
physical,
psychological
therapies
available.
This
review
was
structured
based
on
PubMed
search
papers
published
field
2010
until
May
2019.
International Journal of Molecular Sciences,
Год журнала:
2022,
Номер
23(6), С. 3344 - 3344
Опубликована: Март 19, 2022
Medical
case
reports
suggest
that
cannabinoids
extracted
from
Cannabis
sativa
have
therapeutic
effects;
however,
the
employment
is
limited
due
to
psychotropic
effect
of
its
major
component,
Δ9-tetrahydrocannabinol
(THC).
The
new
scientific
discoveries
related
endocannabinoid
system,
including
receptors,
ligands,
and
mediators,
allowed
development
targets
for
treatment
several
pathological
disorders
minimizing
undesirable
effects
some
constituents
this
plant.
Today,
FDA-approved
drugs,
such
as
nabiximols
(a
mixture
THC
non-psychoactive
cannabidiol
(CBD)),
are
employed
in
alleviating
pain
spasticity
multiple
sclerosis.
Dronabinol
nabilone
used
chemotherapy-induced
nausea
vomiting
cancer
patients.
was
approved
anorexia
patients
with
AIDS
(acquired
immune
deficiency
syndrome).
In
review,
we
highlighted
potential
efficacy
natural
synthetic
their
clinical
relevance
cancer,
neurodegenerative
dermatological
diseases,
viral
infections.
Psychopharmacology,
Год журнала:
2022,
Номер
239(5), С. 1509 - 1519
Опубликована: Янв. 12, 2022
There
has
been
increasing
attention
on
cannabis
use
for
medical
purposes,
but
there
is
currently
a
lack
of
data
its
epidemiology.To
examine
the
epidemiology
self-reported
purposes
by
(1)
estimating
prevalence,
(2)
comparing
gender
and
age
differences,
(3)
investigating
what
reasons
they
were
used
to
manage.Participants
included
27,169
respondents
(aged
16-65)
who
completed
Wave
1
The
International
Cannabis
Policy
Study
(ICPS)
conducted
across
Canada
USA
in
2018
via
online
surveys.
policy
conditions
"US
legal-recreational"
(legal
both
recreational
uses),
legal-medical
only",
illegal",
"Canada-medical
only".The
overall
prevalence
ever
was
27%,
with
similar
rates
sex
highest
young
adults.
Prevalence
higher
US
legal-recreational
states
(34%)
than
illegal
(23%),
only
(25%),
(25%).
most
common
physical
health
include
manage
pain
(53%),
sleep
(46%),
headaches/migraines
(35%),
appetite
(22%),
nausea/vomiting
(21%).
For
mental
reasons,
anxiety
(52%),
depression
(40%),
PTSD/trauma
(17%).
11%
reported
using
managing
other
drug
or
alcohol
4%
psychosis.A
substantial
proportion
North
American
population
variety
including
those
living
jurisdictions
without
legal
markets.
Further
research
needed
understand
safety
efficacy
these
forms
use.
Signal Transduction and Targeted Therapy,
Год журнала:
2022,
Номер
7(1)
Опубликована: Дек. 5, 2022
Abstract
The
outbreak
of
COVID-19
has
become
a
global
crisis,
and
brought
severe
disruptions
to
societies
economies.
Until
now,
effective
therapeutics
against
are
in
high
demand.
Along
with
our
improved
understanding
the
structure,
function,
pathogenic
process
SARS-CoV-2,
many
small
molecules
potential
anti-COVID-19
effects
have
been
developed.
So
far,
several
antiviral
strategies
were
explored.
Besides
directly
inhibition
viral
proteins
such
as
RdRp
M
pro
,
interference
host
enzymes
including
ACE2
proteases,
blocking
relevant
immunoregulatory
pathways
represented
by
JAK/STAT,
BTK,
NF-κB,
NLRP3
pathways,
regarded
feasible
drug
development.
development
treat
achieved
strategies,
computer-aided
lead
compound
design
screening,
natural
product
discovery,
repurposing,
combination
therapy.
Several
representative
remdesivir
paxlovid
proved
or
authorized
emergency
use
countries.
And
candidates
entered
clinical-trial
stage.
Nevertheless,
due
epidemiological
features
variability
issues
it
is
necessary
continue
exploring
novel
COVID-19.
This
review
discusses
current
findings
for
treatment.
Moreover,
their
detailed
mechanism
action,
chemical
structures,
preclinical
clinical
efficacies
discussed.
Medicines,
Год журнала:
2018,
Номер
6(1), С. 3 - 3
Опубликована: Дек. 23, 2018
The
endocannabinoids
system
(ECS)
has
garnered
considerable
interest
as
a
potential
therapeutic
target
in
various
carcinomas
and
cancer-related
conditions
alongside
neurodegenerative
diseases.
Cannabinoids
are
implemented
several
physiological
processes
such
appetite
stimulation,
energy
balance,
pain
modulation
the
control
of
chemotherapy-induced
nausea
vomiting
(CINV).
However,
pharmacokinetics
pharmacodynamics
interactions
could
be
perceived
drug
combinations,
so
this
short
review
we
tried
to
shed
light
on
medicinal
cannabis.
Hitherto,
few
data
have
been
provided
healthcare
practitioners
about
drug⁻drug
cannabinoids
with
other
prescription
medications.
In
general,
usually
well
tolerated,
but
bidirectional
effects
may
expected
concomitant
administered
agents
via
affected
membrane
transporters
(Glycoprotein
p,
breast
cancer
resistance
proteins,
multidrug
proteins)
metabolizing
enzymes
(Cytochrome
P450
UDP-glucuronosyltransferases).
Caution
should
undertaken
closely
monitor
responses
cannabis
users
certain
drugs
guard
their
safety,
especially
for
elderly
people
chronic
diseases
or
kidney
liver
conditions.
Animals,
Год журнала:
2019,
Номер
9(10), С. 832 - 832
Опубликована: Окт. 19, 2019
The
use
of
CBD-rich
hemp
products
is
becoming
popular
among
pet
owners
with
no
long-term
safety
data
related
to
consumption
in
adult
dogs
and
cats.
purpose
this
study
was
determine
the
single-dose
oral
pharmacokinetics
CBD,
provide
a
preliminary
assessment
adverse
effects
during
12-week
administration
using
hemp-based
product
healthy
Eight
each
species
were
provided
2
mg/kg
total
CBD
concentration
orally
twice
daily
for
12
weeks
screening
six
species.
Pharmacokinetics
revealed
mean
maximum
(Cmax)
301
ng/mL
43
ng/mL,
area
under
curve
(AUC)
1297
ng-h/mL
164
ng-h/mL,
time
maximal
(Tmax)
1.4
h
h,
cats,
respectively.
Serum
chemistry
CBC
results
showed
clinically
significant
alterations,
however
one
cat
persistent
rise
alanine
aminotransferase
(ALT)
above
reference
range
duration
trial.
In
an
supplement
administered
every
not
detrimental
based
on
or
biochemistry
values.
Cats
do
appear
absorb
eliminate
differently
than
dogs,
showing
lower
serum
concentrations
excessive
licking
head-shaking
oil
administration.
International Journal of Molecular Sciences,
Год журнала:
2020,
Номер
21(8), С. 2778 - 2778
Опубликована: Апрель 16, 2020
The
endocannabinoid
system
(ECS)
is
one
of
the
most
crucial
systems
in
human
organism,
exhibiting
multi-purpose
regulatory
character.
It
engaged
a
vast
array
physiological
processes,
including
nociception,
mood
regulation,
cognitive
functions,
neurogenesis
and
neuroprotection,
appetite,
lipid
metabolism,
as
well
cell
growth
proliferation.
Thus,
ECS
proteins,
cannabinoid
receptors
their
endogenous
ligands’
synthesizing
degrading
enzymes,
are
promising
therapeutic
targets.
Their
modulation
has
been
employed
or
extensively
studied
treatment
multiple
diseases.
However,
due
to
complex
nature
its
crosstalk
with
other
biological
systems,
development
novel
drugs
turned
out
be
challenging
task.
In
this
review,
we
summarize
potential
applications
for
ECS-targeting
drugs,
especially
focusing
on
synthetic
compounds
preclinical
studies.
We
put
emphasis
specific
proteins
different
pathophysiological
areas.
addition,
stress
possible
difficulties
risks
highlight
proposed
solutions.
By
presenting
point
information
pivotal
spotlight
drug
design,
provide
an
overview
current
state
knowledge
ECS-related
pharmacodynamics
show
directions
needed
research.
